Deep Medicine Acquisition - Tradeable Rights - Oct 2026 Profit Margin

As of the most recent data (June 2026), DMAQR shows a profit margin of -55.68%. That compares with -52.55% in the prior-year period — down 5.9% year over year. That is below the sector sector average of 21.49%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DMAQR's profit margin is now -55.68% (was -52.55%) — a 5.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Deep Medicine Acquisition - Tradeable Rights - Oct 2026 is outperforming or lagging.

The its sector sector average profit margin is about 21.49%. Deep Medicine Acquisition - Tradeable Rights - Oct 2026 is at -55.68%, which is lower that average. That is roughly 359.1% below the sector mean. Use the comparison chart on this page to see how DMAQR stacks up against individual peers as well.

That compares with -52.55% in the prior-year period — down 5.9% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Deep Medicine Acquisition - Tradeable Rights - Oct 2026 with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Deep Medicine Acquisition - Tradeable Rights - Oct 2026's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -55.68%) with ownership activity and broader fundamentals.